These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

454 related articles for article (PubMed ID: 19087274)

  • 1. Proteomic analysis of tumor necrosis factor-alpha resistant human breast cancer cells reveals a MEK5/Erk5-mediated epithelial-mesenchymal transition phenotype.
    Zhou C; Nitschke AM; Xiong W; Zhang Q; Tang Y; Bloch M; Elliott S; Zhu Y; Bazzone L; Yu D; Weldon CB; Schiff R; McLachlan JA; Beckman BS; Wiese TE; Nephew KP; Shan B; Burow ME; Wang G
    Breast Cancer Res; 2008; 10(6):R105. PubMed ID: 19087274
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MEK5/ERK5 signaling suppresses estrogen receptor expression and promotes hormone-independent tumorigenesis.
    Antoon JW; Martin EC; Lai R; Salvo VA; Tang Y; Nitzchke AM; Elliott S; Nam SY; Xiong W; Rhodes LV; Collins-Burow B; David O; Wang G; Shan B; Beckman BS; Nephew KP; Burow ME
    PLoS One; 2013; 8(8):e69291. PubMed ID: 23950888
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MEK5 is activated by shear stress, activates ERK5 and induces KLF4 to modulate TNF responses in human dermal microvascular endothelial cells.
    Clark PR; Jensen TJ; Kluger MS; Morelock M; Hanidu A; Qi Z; Tatake RJ; Pober JS
    Microcirculation; 2011 Feb; 18(2):102-17. PubMed ID: 21166929
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A kinome-wide high-content siRNA screen identifies MEK5-ERK5 signaling as critical for breast cancer cell EMT and metastasis.
    Pavan S; Meyer-Schaller N; Diepenbruck M; Kalathur RKR; Saxena M; Christofori G
    Oncogene; 2018 Aug; 37(31):4197-4213. PubMed ID: 29713055
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Upregulation of MEK5 by Stat3 promotes breast cancer cell invasion and metastasis.
    Liu F; Zhang H; Song H
    Oncol Rep; 2017 Jan; 37(1):83-90. PubMed ID: 27878304
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SLUG/SNAI2 and tumor necrosis factor generate breast cells with CD44+/CD24- phenotype.
    Bhat-Nakshatri P; Appaiah H; Ballas C; Pick-Franke P; Goulet R; Badve S; Srour EF; Nakshatri H
    BMC Cancer; 2010 Aug; 10():411. PubMed ID: 20691079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual inhibition of MEK1/2 and MEK5 suppresses the EMT/migration axis in triple-negative breast cancer through FRA-1 regulation.
    Hoang VT; Matossian MD; La J; Hoang K; Ucar DA; Elliott S; Burks HE; Wright TD; Patel S; Bhatt A; Phamduy T; Chrisey D; Buechlein A; Rusch DB; Nephew KP; Anbalagan M; Rowan B; Cavanaugh JE; Flaherty PT; Miele L; Collins-Burow BM; Burow ME
    J Cell Biochem; 2021 Aug; 122(8):835-850. PubMed ID: 33876843
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of mitogen-activated protein kinase kinase as a chemoresistant pathway in MCF-7 cells by using gene expression microarray.
    Weldon CB; Scandurro AB; Rolfe KW; Clayton JL; Elliott S; Butler NN; Melnik LI; Alam J; McLachlan JA; Jaffe BM; Beckman BS; Burow ME
    Surgery; 2002 Aug; 132(2):293-301. PubMed ID: 12219026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nuclear beta-catenin and CD44 upregulation characterize invasive cell populations in non-aggressive MCF-7 breast cancer cells.
    Uchino M; Kojima H; Wada K; Imada M; Onoda F; Satofuka H; Utsugi T; Murakami Y
    BMC Cancer; 2010 Aug; 10():414. PubMed ID: 20696077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Generation of MCF-7 cells with aggressive metastatic potential in vitro and in vivo.
    Ziegler E; Hansen MT; Haase M; Emons G; Gründker C
    Breast Cancer Res Treat; 2014 Nov; 148(2):269-77. PubMed ID: 25292421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological inhibition of the MEK5/ERK5 and PI3K/Akt signaling pathways synergistically reduces viability in triple-negative breast cancer.
    Wright TD; Raybuck C; Bhatt A; Monlish D; Chakrabarty S; Wendekier K; Gartland N; Gupta M; Burow ME; Flaherty PT; Cavanaugh JE
    J Cell Biochem; 2020 Feb; 121(2):1156-1168. PubMed ID: 31464004
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The MEK5-ERK5 Kinase Axis Controls Lipid Metabolism in Small-Cell Lung Cancer.
    Cristea S; Coles GL; Hornburg D; Gershkovitz M; Arand J; Cao S; Sen T; Williamson SC; Kim JW; Drainas AP; He A; Cam LL; Byers LA; Snyder MP; Contrepois K; Sage J
    Cancer Res; 2020 Mar; 80(6):1293-1303. PubMed ID: 31969375
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fatty acid synthase mediates the epithelial-mesenchymal transition of breast cancer cells.
    Li J; Dong L; Wei D; Wang X; Zhang S; Li H
    Int J Biol Sci; 2014; 10(2):171-80. PubMed ID: 24520215
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resistance to MAPK Inhibitors in Melanoma Involves Activation of the IGF1R-MEK5-Erk5 Pathway.
    Benito-Jardón L; Díaz-Martínez M; Arellano-Sánchez N; Vaquero-Morales P; Esparís-Ogando A; Teixidó J
    Cancer Res; 2019 May; 79(9):2244-2256. PubMed ID: 30833419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SATB2 suppresses the progression of colorectal cancer cells via inactivation of MEK5/ERK5 signaling.
    Mansour MA; Hyodo T; Ito S; Kurita K; Kokuryo T; Uehara K; Nagino M; Takahashi M; Hamaguchi M; Senga T
    FEBS J; 2015 Apr; 282(8):1394-405. PubMed ID: 25662172
    [TBL] [Abstract][Full Text] [Related]  

  • 16. YAP promotes myogenic differentiation
    Chen TH; Chen CY; Wen HC; Chang CC; Wang HD; Chuu CP; Chang CH
    FASEB J; 2017 Jul; 31(7):2963-2972. PubMed ID: 28356344
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MEK5/ERK5 signaling inhibition increases colon cancer cell sensitivity to 5-fluorouracil through a p53-dependent mechanism.
    Pereira DM; Simões AE; Gomes SE; Castro RE; Carvalho T; Rodrigues CM; Borralho PM
    Oncotarget; 2016 Jun; 7(23):34322-40. PubMed ID: 27144434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ERK5 signalling in prostate cancer promotes an invasive phenotype.
    Ramsay AK; McCracken SR; Soofi M; Fleming J; Yu AX; Ahmad I; Morland R; Machesky L; Nixon C; Edwards DR; Nuttall RK; Seywright M; Marquez R; Keller E; Leung HY
    Br J Cancer; 2011 Feb; 104(4):664-72. PubMed ID: 21266977
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular Mechanisms of Epithelial to Mesenchymal Transition Regulated by ERK5 Signaling.
    Bhatt AB; Patel S; Matossian MD; Ucar DA; Miele L; Burow ME; Flaherty PT; Cavanaugh JE
    Biomolecules; 2021 Jan; 11(2):. PubMed ID: 33572742
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MEK5/ERK5 pathway: the first fifteen years.
    Drew BA; Burow ME; Beckman BS
    Biochim Biophys Acta; 2012 Jan; 1825(1):37-48. PubMed ID: 22020294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.